Quality prescribing in early psychosis: key pharmacotherapy principles

Australas Psychiatry. 2022 Jun;30(3):341-345. doi: 10.1177/10398562211054656. Epub 2021 Nov 8.

Abstract

Objective: To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis.

Method: Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience.

Results: Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk-benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met.

Conclusions: Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.

Keywords: antipsychotic medications; early psychosis; maintenance treatment; prescribing practices.

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Clozapine* / therapeutic use
  • Humans
  • Psychotic Disorders* / drug therapy

Substances

  • Antipsychotic Agents
  • Clozapine